WO2024026302A3 - Compositions and methods for adeno-associated viral production - Google Patents

Compositions and methods for adeno-associated viral production Download PDF

Info

Publication number
WO2024026302A3
WO2024026302A3 PCT/US2023/070927 US2023070927W WO2024026302A3 WO 2024026302 A3 WO2024026302 A3 WO 2024026302A3 US 2023070927 W US2023070927 W US 2023070927W WO 2024026302 A3 WO2024026302 A3 WO 2024026302A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
adeno
compositions
genetically engineered
associated viral
Prior art date
Application number
PCT/US2023/070927
Other languages
French (fr)
Other versions
WO2024026302A2 (en
Inventor
Jeremy J. GAM
Alec A.K. NIELSEN
Jeffrey B. MCMAHAN
Original Assignee
Asimov Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asimov Inc. filed Critical Asimov Inc.
Publication of WO2024026302A2 publication Critical patent/WO2024026302A2/en
Publication of WO2024026302A3 publication Critical patent/WO2024026302A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22Ribonucleases RNAses, DNAses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10344Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151Methods of production or purification of viral material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/30Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/50Vectors for producing vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00Vectors comprising a special translation-regulating system
    • C12N2840/44Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Disclosed herein are cell genetically engineered cells for AAV production. The genetically engineered cells comprise molecular systems for temporal control of expression of genes required for AAV production. Also disclosed herein are methods of using genetically engineered cells for AAV production. Further, wherein the expression control component comprises a polynucleic acid molecule encoding for a recombinase.
PCT/US2023/070927 2022-07-26 2023-07-25 Compositions and methods for adeno-associated viral production WO2024026302A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263369476P 2022-07-26 2022-07-26
US63/369,476 2022-07-26

Publications (2)

Publication Number Publication Date
WO2024026302A2 WO2024026302A2 (en) 2024-02-01
WO2024026302A3 true WO2024026302A3 (en) 2024-03-28

Family

ID=89707269

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/070927 WO2024026302A2 (en) 2022-07-26 2023-07-25 Compositions and methods for adeno-associated viral production

Country Status (1)

Country Link
WO (1) WO2024026302A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006020480A2 (en) * 2004-08-09 2006-02-23 Merck & Co., Inc. Adenoviral vector compositions
US20210348194A1 (en) * 2018-10-05 2021-11-11 Voyager Therapeutics, Inc. Engineered nucleic acid constructs encoding aav production proteins
WO2021226558A1 (en) * 2020-05-08 2021-11-11 The Broad Institute, Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
WO2022015788A1 (en) * 2020-07-14 2022-01-20 Abeona Therapeutics Inc. Recombinant adeno-associated viral vectors for multipartite gene delivery
US20220154223A1 (en) * 2020-10-15 2022-05-19 Hoffmann-La Roche Inc. Nucleic acid constructs for simultaneous gene activation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006020480A2 (en) * 2004-08-09 2006-02-23 Merck & Co., Inc. Adenoviral vector compositions
US20210348194A1 (en) * 2018-10-05 2021-11-11 Voyager Therapeutics, Inc. Engineered nucleic acid constructs encoding aav production proteins
WO2021226558A1 (en) * 2020-05-08 2021-11-11 The Broad Institute, Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
WO2022015788A1 (en) * 2020-07-14 2022-01-20 Abeona Therapeutics Inc. Recombinant adeno-associated viral vectors for multipartite gene delivery
US20220154223A1 (en) * 2020-10-15 2022-05-19 Hoffmann-La Roche Inc. Nucleic acid constructs for simultaneous gene activation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AU HAU KIU EDNA, ISALAN MARK, MIELCAREK MICHAL: "Gene Therapy Advances: A Meta-Analysis of AAV Usage in Clinical Settings", FRONTIERS IN MEDICINE, vol. 8, XP093044395, DOI: 10.3389/fmed.2021.809118 *

Also Published As

Publication number Publication date
WO2024026302A2 (en) 2024-02-01

Similar Documents

Publication Publication Date Title
EP2061891A4 (en) Expression in insect cells of genes with overlapping open reading frames, methods and compositions therefor
EP2110875A4 (en) Polymer electrolyte membrane, method for producing the same, membrane-electrode assembly and solid polymer fuel cell
Sergeeva et al. Multicopy targeted integration for accelerated development of high-producing Chinese hamster ovary cells
WO2008021140A3 (en) Recombinant aav production in mammalian cells
WO2020127417A3 (en) PRODUCTION OF 3-FUCOSYLLACTOSE AND LACTOSE CONVERTING α-1,3-FUCOSYLTRANSFERASE ENZYMES
HK1046926A1 (en) Methods and compositions for directed cloning and subcloning using homologous recombination.
WO2006012414A3 (en) Novel polyadenylation signal for use in expression vectors
WO2012172277A4 (en) Simian adenovirus and hybrid adenoviral vectors
JP2011504721A5 (en)
WO2005001037A3 (en) Electrolyte membranes based on alkyloxysilane grafted thermoplastic polymers
IN2005MU00356A (en)
WO2024026302A3 (en) Compositions and methods for adeno-associated viral production
JP4685037B2 (en) Polymer, cross-linked polymer, composition for polymer solid electrolyte, polymer solid electrolyte, and adhesive composition
BR112021026326A2 (en) Engineered sucrose phosphorylase, composition, polynucleotide sequence, expression vector, host cell, and method for producing an engineered sucrose phosphorylase
WO2004027048A3 (en) High titer recombinant aav production
WO2021016227A8 (en) Synthetic genetic elements for biomanufacture
CN112029699A (en) Clostridium butyricum gene editing system based on endogenous CRISPR-Cas system and application thereof
WO2022236080A3 (en) Compositions and methods for adeno-associated viral production
EP1918330A4 (en) Ion-conductive material, solid polymer electrolyte membrane, and fuel battery
AU2003233855A1 (en) Low-viscosity polyisocyanate composition having high functionality and method for preparing same
WO2021231488A3 (en) D-allulose 3-epimerases for bioconversion of d-fructose to d-allulose
MX2022013477A (en) Miniaturized dystrophins having spectrin fusion domains and uses thereof.
WO2021195491A3 (en) Inducible promoter for viral vector production
WO2021231263A3 (en) Nucleic acid amplification methods
BR112021024819A2 (en) Engineered acetate kinase, composition, polynucleotide sequence, expression vector, host cell, and production method of an engineered acetate kinase

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23847502

Country of ref document: EP

Kind code of ref document: A2